Drug Profile
Hydroxychloroquine sulfate inhalation - Pulmoquine Therapeutics
Alternative Names: aHCQ - Pulmoquine TherapueitcsLatest Information Update: 28 Jul 2023
Price :
$50
*
At a glance
- Originator Pulmoquine Therapeutics
- Class Antimalarials; Antivirals; Chlorobenzenes; Disease-modifying antirheumatics; Ethanolamines; Quinolines; Small molecules
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported COVID 2019 infections
Most Recent Events
- 28 Jul 2023 No recent reports of development identified for phase-I development in COVID-2019-infections(In volunteers) in USA (PO, Aerosol)
- 25 Jun 2020 Phase-I clinical trials in COVID-2019 infections (In volunteers) in USA (PO) (NCT04461353)